Anti-nectin-4-antibody exatecan conjugates
AssigneesEmergence Therapeutics AG, Université d' Aix-Marseille, Inserm (Institut National De La Sante Et De La Recherche Medicale), Institut Jean Paoli & Irene Calmettes, Centre National de la Recherche Scientifique (CNRS)
InventorsJack ELANDS, Florence LHOSPPICE, Xavier PRÉVILLE, Daniel OLIVE, Marc LOPEZ
Life of this patent
Estimating the term…
Abstract
The present invention relates to an antibody -drug conjugate comprising a monoclonal antibody or an antigen-binding fragment thereof wherein the monoclonal antibody or the antigen-binding fragment thereof binds to Nectin-4 and wherein the drug is a topoisomerase I inhibitor, particularly exatecan.
Claims23
An antibody-drug conjugate comprising a monoclonal antibody or an antigen-binding fragment thereof and a drug, wherein the monoclonal antibody or the antigen-binding fragment thereof binds to Nectin-4, and the drug is a topoisomerase I inhibitor.
A pharmaceutical composition comprising an active agent, which is an antibody-drug conjugate comprising a monoclonal antibody or an antigen-binding fragment thereof wherein the monoclonal antibody or the antigen-binding fragment thereof binds to Nectin-4 and wherein the drug is a topoisomerase I inhibitor, and a pharmaceutically acceptable carrier and/or excipient.
Dependencies are inferred from the claim text.